BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,130 filers reported holding BAXTER INTL INC in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $202,000 | -16.2% | 3,750 | 0.0% | 0.02% | -10.0% |
| Q2 2022 | $241,000 | -17.2% | 3,750 | 0.0% | 0.02% | -4.8% |
| Q1 2022 | $291,000 | -9.6% | 3,750 | 0.0% | 0.02% | -4.5% |
| Q4 2021 | $322,000 | +5.6% | 3,750 | 0.0% | 0.02% | -4.3% |
| Q3 2021 | $305,000 | +1.0% | 3,750 | 0.0% | 0.02% | 0.0% |
| Q2 2021 | $302,000 | -4.4% | 3,750 | 0.0% | 0.02% | -8.0% |
| Q1 2021 | $316,000 | +5.0% | 3,750 | 0.0% | 0.02% | +4.2% |
| Q4 2020 | $301,000 | -0.3% | 3,750 | 0.0% | 0.02% | -7.7% |
| Q3 2020 | $302,000 | -7.4% | 3,750 | -1.1% | 0.03% | -10.3% |
| Q2 2020 | $326,000 | -6.3% | 3,790 | -11.7% | 0.03% | -17.1% |
| Q1 2020 | $348,000 | -3.1% | 4,290 | 0.0% | 0.04% | +16.7% |
| Q4 2019 | $359,000 | -4.3% | 4,290 | 0.0% | 0.03% | -3.2% |
| Q3 2019 | $375,000 | +6.8% | 4,290 | 0.0% | 0.03% | +6.9% |
| Q2 2019 | $351,000 | -14.4% | 4,290 | -14.9% | 0.03% | -14.7% |
| Q1 2019 | $410,000 | +23.5% | 5,040 | 0.0% | 0.03% | +9.7% |
| Q4 2018 | $332,000 | -14.4% | 5,040 | 0.0% | 0.03% | -3.1% |
| Q3 2018 | $388,000 | +4.3% | 5,040 | 0.0% | 0.03% | -3.0% |
| Q2 2018 | $372,000 | +13.4% | 5,040 | 0.0% | 0.03% | +10.0% |
| Q1 2018 | $328,000 | +0.6% | 5,040 | 0.0% | 0.03% | +7.1% |
| Q4 2017 | $326,000 | +2.8% | 5,040 | 0.0% | 0.03% | 0.0% |
| Q3 2017 | $317,000 | +3.9% | 5,040 | 0.0% | 0.03% | 0.0% |
| Q2 2017 | $305,000 | +16.0% | 5,040 | -0.8% | 0.03% | +16.7% |
| Q1 2017 | $263,000 | +16.4% | 5,080 | 0.0% | 0.02% | +14.3% |
| Q4 2016 | $226,000 | -7.4% | 5,080 | -0.8% | 0.02% | -4.5% |
| Q3 2016 | $244,000 | -2.0% | 5,120 | -7.1% | 0.02% | -4.3% |
| Q2 2016 | $249,000 | +9.7% | 5,510 | 0.0% | 0.02% | +9.5% |
| Q1 2016 | $227,000 | -15.0% | 5,510 | -21.2% | 0.02% | -19.2% |
| Q4 2015 | $267,000 | -20.8% | 6,995 | -31.7% | 0.03% | -23.5% |
| Q3 2015 | $337,000 | -77.0% | 10,245 | -51.1% | 0.03% | -75.0% |
| Q2 2015 | $1,464,000 | -24.1% | 20,935 | -25.6% | 0.14% | -22.7% |
| Q1 2015 | $1,928,000 | -1.1% | 28,145 | +5.7% | 0.18% | +2.3% |
| Q4 2014 | $1,950,000 | +1.2% | 26,615 | -0.8% | 0.17% | +0.6% |
| Q3 2014 | $1,926,000 | +64.5% | 26,835 | +65.8% | 0.17% | +69.3% |
| Q2 2014 | $1,171,000 | +4.8% | 16,190 | +6.7% | 0.10% | 0.0% |
| Q1 2014 | $1,117,000 | +141.3% | 15,175 | +128.2% | 0.10% | +129.5% |
| Q4 2013 | $463,000 | +5.9% | 6,650 | 0.0% | 0.04% | 0.0% |
| Q3 2013 | $437,000 | -5.2% | 6,650 | 0.0% | 0.04% | -8.3% |
| Q2 2013 | $461,000 | – | 6,650 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |